Asaf Biber

Asaf Biber

Auto-generated profile, based on publicly available information

Asaf Biber

Infectious Diseases Unit, The Center for Geographic Medicine and Tropical Diseases, Sheba Medical Center, Ramat-Gan, Israel

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GRGili Regev-Yochay
Gili Regev-Yochay
TGTal Gonen
Tal Gonen
MGMayan Gilboa
Mayan Gilboa
MMMichal Mandelboim
Michal Mandelboim
VIVictoria Indenbaum
Victoria Indenbaum
YLYaniv Lustig
Yaniv Lustig
In this open-label, nonrandomized clinical study, we assessed the immunogenicity and safety of a fourth dose of either BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) administered 4 months after the third dose in a series of three BNT162b2 doses (ClinicalTrials.gov numbers, NCT05231005 and NCT05230953; the protocol is available with the full text of this letter at NEJM.org). Of the 1050 eligible health care workers enrolled in the Sheba HCW COVID-19 Cohort,1,2 154 received the fourth dose of BNT162b2 and, 1 week later, 120 received mRNA-1273. For each participant, two age-matched controls were selected from the remaining eligible participants (Fig. S1 in the Supplementary Appendix, available at NEJM.org).

24 November 2021 in Cell Reports
Verified
Journal Article
Open access
IFInbal Farkash
Inbal Farkash
Tali FefermanTali Feferman
Tali Feferman
NCNoy Cohen-Saban
Noy Cohen-Saban
YAYahel Avraham
Yahel Avraham
DMDavid Morgenstern
David Morgenstern
RDRony Dahan
Rony Dahan
Messenger RNA-based vaccines against COVID-19 induce a robust anti-SARS-CoV-2 antibody response with potent viral neutralization activity. Antibody effector functions are determined by their constant region subclasses and by their glycosylation patterns, but their role in vaccine efficacy is unclear. Moreover, whether vaccination induces antibodies similar to those in patients with COVID-19 remains unknown. We analyze BNT162b2 vaccine-induced IgG subclass distribution and Fc glycosylation patterns and their potential to drive effector function via Fcγ receptors and complement pathways. We identify unique and dynamic pro-inflammatory Fc compositions that are distinct from those in patients with COVID-19 and convalescents. Vaccine-induced anti-Spike IgG is characterized by distinct Fab- and Fc-mediated functions between different age groups and in comparison to antibodies generated during natural viral infection. These data highlight the heterogeneity of Fc responses to SARS-CoV-2 infection and vaccination and suggest that they support long-lasting protection differently.

16 August 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAsaf Biber
Asaf Biber
IAIzeldeen Abuelaish
Izeldeen Abuelaish
GRGalia Rahav
Galia Rahav
MRMeir Raz
Meir Raz
LCLiran Cohen
Liran Cohen
FGfor the PICR Study Group
for the PICR Study Group
Epidemiological data on community acquired methicillin-resistant-Staphylococcus aureus (CA-MRSA) carriage and infection in the Middle-East region is scarce with only few reports in the Israeli and Palestinian populations. As part of a Palestinian-Israeli collaborative research, we have conducted a cross-sectional survey of nasal S. aureus carriage in healthy children and their parents throughout the Gaza strip. Isolates were characterized for antibiotic susceptibility, mec gene presence, PFGE, spa type, SCCmec-type, presence of PVL genes and multi-locus-sequence-type (MLST). S. aureus was carried by 28.4% of the 379 screened children-parents pairs. MRSA was detected in 45% of S. aureus isolates, that is, in 12% of the study population. A single ST22-MRSA-IVa, spa t223, PVL-gene negative strain was detected in 64% of MRSA isolates. This strain is typically susceptible to all non-β-lactam antibiotics tested. The only predictor for MRSA carriage in children was having an MRSA carrier-parent (OR = 25.5, P = 0.0004). Carriage of the Gaza strain was not associated with prior hospitalization. The Gaza strain was closely related genetically to a local MSSA spa t223 strain and less so to EMRSA15, one of the pandemic hospital-acquired-MRSA clones, scarcely reported in the community. The rapid spread in the community may be due to population determinants or due to yet unknown advantageous features of this particular strain.

14 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
NLNoemia S. Lima
Noemia S. Lima
MMMaryam Musayev
Maryam Musayev
TJTimothy S. Johnston
Timothy S. Johnston
DWDanielle A. Wagner
Danielle A. Wagner
AHAmy R. Henry
Amy R. Henry
DDDaniel C. Douek
Daniel C. Douek
An important consequence of infection with a SARS-CoV-2 variant is protective humoral immunity against other variants. However, the basis for such cross-protection at the molecular level is incompletely understood. Here, we characterized the repertoire and epitope specificity of antibodies elicited by infection with the Beta, Gamma and WA1 ancestral variants and assessed their cross-reactivity to these and the more recent Delta and Omicron variants. We developed a method to obtain immunoglobulin sequences with concurrent rapid production and functional assessment of monoclonal antibodies from hundreds of single B cells sorted by flow cytometry. Infection with any variant elicited similar cross-binding antibody responses exhibiting a conserved hierarchy of epitope immunodominance. Furthermore, convergent V gene usage and similar public B cell clones were elicited regardless of infecting variant. These convergent responses despite antigenic variation may account for the continued efficacy of vaccines based on a single ancestral variant.

1 November 2018 in Emerging Infectious Diseases
Verified
Journal Article
Open access
NPNestor Pakasa
Nestor Pakasa
ABAsaf Biber
Asaf Biber
SNSamuel Nsiangana
Samuel Nsiangana
DIDésiré Imposo
Désiré Imposo
ESErnest Sumaili
Ernest Sumaili
ESEli Schwartz
Eli Schwartz
We describe a case series of histoplasmosis caused by Histoplasma capsulatum var. duboisii during July 2011–January 2014 in Kimpese, Democratic Republic of the Congo. Cases were confirmed by histopathology, immunohistochemistry, and reverse transcription PCR. All patients were HIV negative. Putative sources for the pathogen were cellar bats and guano fertilizer exploitation.

8 July 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
ABAsaf Biber
Asaf Biber
GHGeva Harmelin
Geva Harmelin
DLDana Lev
Dana Lev
LRLi Ram
Li Ram
ASAmit Shaham
Amit Shaham
Eli SchwartzEli Schwartz
Eli Schwartz
Ivermectin, an antiparasitic agent, also has antiviral properties. In this study, we aimed to assess whether ivermectin has anti-SARS-CoV-2 activity. In this double-blinded trial, we compared patients receiving ivermectin for 3 days versus placebo in nonhospitalized adult patients with COVID-19. A reverse transcriptase-polymerase chain reaction from a nasopharyngeal swab was obtained at recruitment and every 2 days for at least 6 days. The primary endpoint was a reduction of viral load on the sixth day as reflected by cycle threshold level >30 (noninfectious level). The primary outcome was supported by the determination of viral-culture viability. Of 867 patients screened, 89 were ultimately evaluated per-protocol (47 ivermectin and 42 placeboes). On day 6, the odds ratio (OR) was 2.62 (95% confidence interval [CI]: 1.09-6.31) in the ivermectin arm, reaching the endpoint. In a multivariable logistic regression model, the odds of a negative test on day 6 were 2.28 times higher in the ivermectin group but reached significance only on day 8 (OR 3.70; 95% CI: 1.19-11.49, P = 0.02). Culture viability on days 2 to 6 was positive in 13.0% (3/23) of ivermectin samples versus 48.2% (14/29) in the placebo group (P = 0.008). There were lower viral loads and less viable cultures in the ivermectin group, which shows its anti-SARS-CoV-2 activity. It could reduce transmission in these patients and encourage further studies with this drug.